/APUS
APUS Stock - Apimeds Pharmaceuticals US, Inc
Healthcare|Drug Manufacturers - Specialty & GenericNYSE
$1.52-14.12%
$0.25 (-14.12%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APUS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.50 – $1.54
TARGET (TP)$1.75
STOP LOSS$1.40
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-6.48
52W High$4.03
52W Low$1.37
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-1,275,095 | $-747,436 | $-639,529 | $-1,019,494 |
| Net Income | $-1,389,990 | $-777,694 | $-668,666 | $-1,026,234 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-0.12 | $-0.07 | $-0.06 | $-0.09 |
Company Overview
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
APUSBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-0.14 | — | — |
Q3 2025 | Aug 19, 2025 | — | $-0.26 | — | — |
Latest News
Reported Earlier: Apimeds Pharma Announces Merger With MindWave Innovations; No Financial Terms Disclosed
➖ NeutralBenzinga•Dec 1, 2025, 02:51 PM
Apimeds Pharmaceuticals Shares Resume Trade
➖ NeutralBenzinga•Dec 1, 2025, 02:50 PM
Apimeds Pharma Announces Merger With MindWave Innovations Uniting Apimeds' Late-Stage, Non-Opioid Pain-Management Biologic Portfolio With MindWave's AI-Driven Digital Treasury
📈 PositiveBenzinga•Dec 1, 2025, 02:32 PM
Apimeds Expands ai Futures Lab With University Of Oregon Partnership To Advance Biopharma Innovation And Train Next-Generation Healthcare Leaders
📈 PositiveBenzinga•Oct 14, 2025, 07:19 AM
Reported Earlier, Apimeds And University Of San Diego Partner To Advance Future Labs Program Developing Next Generation Biopharma Business Talent
📈 PositiveBenzinga•Sep 16, 2025, 07:13 AM
Reported Earlier, Apimeds Highlights FDA Draft Guidance On Non-Opioid Analgesics As Key Milestone For Advancing Late-Stage Apitox Pain Therapy
📈 PositiveBenzinga•Sep 12, 2025, 07:31 AM
Apimeds Pharmaceuticals Q2 EPS $(0.26) Down From $(0.06) YoY
📉 NegativeBenzinga•Aug 19, 2025, 09:50 PM
Frequently Asked Questions about APUS
What is APUS's current stock price?
Apimeds Pharmaceuticals US, Inc (APUS) is currently trading at $1.52 per share. The stock has moved -14.12% today.
What is the analyst price target for APUS?
No analyst price targets are currently available for this stock.
What sector is Apimeds Pharmaceuticals US, Inc in?
Apimeds Pharmaceuticals US, Inc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.
What is APUS's market cap?
Apimeds Pharmaceuticals US, Inc has a market capitalization of $0.02 billion, making it a small-cap company.
Does APUS pay dividends?
No, Apimeds Pharmaceuticals US, Inc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
IGC
IGC Pharma, Inc.
$0.30
Mkt Cap: $0.0B
MIRA
MIRA Pharmaceuticals, Inc.
$1.63
Mkt Cap: $0.1B
MLSS
Milestone Scientific Inc.
$0.32
Mkt Cap: $0.0B
MYO
Myomo, Inc.
$0.93
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
POCI
Precision Optics Corporation, Inc.
$4.08
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SCYX
SCYNEXIS, Inc.
$0.63
Mkt Cap: $0.0B
TLPH
Talphera, Inc.
$1.10
Mkt Cap: $0.0B
Explore stocks similar to APUS for comparison